(Q37773845)

22 August 2017

1 reference

title

Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? (English)

1 reference

22 August 2017

main subject

chronic myeloid leukemia

0 references

1 reference

3

Hagop Kantarjian

1 reference

22 August 2017

4

Jorge Cortes

1 reference

22 August 2017

2

Ravin J Garg

1 reference

22 August 2017

1

Meetu Agrawal

1 reference

22 August 2017

publication date

1 September 2010

1 reference

22 August 2017

published in

Current Oncology Reports

1 reference

22 August 2017

volume

12

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

302-313

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-010-0116-1

22 August 2017

exact match

0 references

cites work

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-010-0116-1

Interferon alpha and T-cell responses in chronic myeloid leukemia

21 January 2018

1 reference

12 December 2020

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

1 reference

12 December 2020

The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.

1 reference

12 December 2020

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

1 reference

12 December 2020

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

12 December 2020

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

12 December 2020

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

1 reference

12 December 2020

Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia

1 reference

12 December 2020

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

1 reference

12 December 2020

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

1 reference

12 December 2020

Chronic myeloid leukemia: molecular monitoring in clinical practice

1 reference

12 December 2020

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

1 reference

12 December 2020

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

1 reference

12 December 2020

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate

1 reference

12 December 2020

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

12 December 2020

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

12 December 2020

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

12 December 2020

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial

1 reference

12 December 2020

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

12 December 2020

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

1 reference

12 December 2020

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

1 reference

12 December 2020

Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

1 reference

12 December 2020

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

12 December 2020

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

1 reference

12 December 2020

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

1 reference

12 December 2020

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

1 reference

12 December 2020

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

1 reference

12 December 2020

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

12 December 2020

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

12 December 2020

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

12 December 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

1 reference

12 December 2020

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

1 reference

12 December 2020

10.1007/S11912-010-0116-1

Identifiers

DOI

1 reference

22 August 2017

1 reference